Citigroup Inc. Has $20.91 Million Holdings in Haemonetics Corporation $HAE

Citigroup Inc. trimmed its position in Haemonetics Corporation (NYSE:HAE) by 89.8% in the third quarter, HoldingsChannel.com reports. The firm owned 429,041 shares of the medical instruments supplier’s stock after selling 3,769,576 shares during the period. Citigroup Inc.’s holdings in Haemonetics were worth $20,911,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of HAE. Parkside Financial Bank & Trust lifted its holdings in shares of Haemonetics by 11.6% during the 2nd quarter. Parkside Financial Bank & Trust now owns 1,461 shares of the medical instruments supplier’s stock worth $109,000 after acquiring an additional 152 shares during the period. Retirement Systems of Alabama lifted its stake in Haemonetics by 0.4% during the second quarter. Retirement Systems of Alabama now owns 61,401 shares of the medical instruments supplier’s stock worth $4,581,000 after purchasing an additional 256 shares during the period. Teacher Retirement System of Texas lifted its stake in Haemonetics by 3.9% during the second quarter. Teacher Retirement System of Texas now owns 7,636 shares of the medical instruments supplier’s stock worth $570,000 after purchasing an additional 285 shares during the period. Quantinno Capital Management LP boosted its holdings in Haemonetics by 9.0% during the second quarter. Quantinno Capital Management LP now owns 3,492 shares of the medical instruments supplier’s stock valued at $261,000 after purchasing an additional 289 shares in the last quarter. Finally, CWC Advisors LLC. grew its stake in shares of Haemonetics by 7.8% in the 3rd quarter. CWC Advisors LLC. now owns 4,551 shares of the medical instruments supplier’s stock valued at $222,000 after purchasing an additional 328 shares during the period. Institutional investors and hedge funds own 99.67% of the company’s stock.

Haemonetics Price Performance

HAE opened at $62.21 on Friday. The company has a debt-to-equity ratio of 1.01, a current ratio of 1.75 and a quick ratio of 1.15. The company’s 50 day simple moving average is $70.47 and its 200-day simple moving average is $63.96. Haemonetics Corporation has a one year low of $47.31 and a one year high of $87.32. The stock has a market capitalization of $2.89 billion, a P/E ratio of 17.14, a price-to-earnings-growth ratio of 1.30 and a beta of 0.28.

Haemonetics (NYSE:HAE) last posted its quarterly earnings data on Thursday, February 5th. The medical instruments supplier reported $1.31 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.27 by $0.04. The firm had revenue of $338.97 million for the quarter, compared to the consensus estimate of $331.90 million. Haemonetics had a return on equity of 27.32% and a net margin of 13.31%.The business’s revenue for the quarter was down 2.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $1.19 EPS. Haemonetics has set its FY 2026 guidance at 4.900-5.000 EPS. Sell-side analysts anticipate that Haemonetics Corporation will post 4.55 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently commented on the company. JPMorgan Chase & Co. boosted their price target on Haemonetics from $62.00 to $74.00 and gave the company a “neutral” rating in a research note on Friday, December 12th. Citigroup reduced their target price on shares of Haemonetics from $88.00 to $75.00 and set a “neutral” rating on the stock in a research note on Friday, February 6th. Wall Street Zen raised shares of Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, January 10th. Weiss Ratings reissued a “hold (c)” rating on shares of Haemonetics in a report on Monday, December 29th. Finally, Mizuho decreased their price objective on shares of Haemonetics from $90.00 to $80.00 and set an “outperform” rating on the stock in a research note on Friday, February 6th. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating and four have given a Hold rating to the stock. According to MarketBeat.com, Haemonetics presently has an average rating of “Moderate Buy” and a consensus target price of $84.44.

Haemonetics News Roundup

Here are the key news stories impacting Haemonetics this week:

• Positive Sentiment: Zacks nudged FY2026 EPS slightly higher to $4.95 (from $4.93), and raised its Q2 2027 estimate to $1.37 (from $1.35) — small upside near‑term beats that may cushion downside from other cuts. Zacks estimate updates (Feb 24)
• Neutral Sentiment: Zacks published a comprehensive set of updated quarterly and fiscal estimates (Q4 2026 – Q3 2028 and FY2026–FY2028), providing a refreshed model investors can use to re‑rate the stock. Zacks estimate updates (Feb 24)
• Negative Sentiment: Material downward revisions to the medium/longer term: Zacks cut FY2028 EPS to $5.73 from $5.90 and trimmed FY2027 to $5.34 from $5.37 — signaling lower expected growth beyond FY2026. Zacks estimate updates (Feb 24)
• Negative Sentiment: Zacks lowered multiple quarterly forecasts across 2026–2028 (examples: Q1 2028 to $1.35 from $1.39; Q1 2027 to $1.19 from $1.20; Q3 2028 to $1.51 from $1.53; Q2 2028 to $1.46 from $1.50; Q4 2027 and Q4 2026 also trimmed). These repeated downgrades put near‑term EPS risk on the table. Zacks estimate updates (Feb 24–25)

Haemonetics Company Profile

Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.

The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.